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Probiotics — let’s get the strains
right before we even try to count
them!
To the Editor: In response to rebuttals published in the March1
and April2,3 2004 issues of the SAMJ, the study ‘An evaluation
of nine probiotics on the South African market’4 published in
the February issue is less about the recognised benefits and
more about the quality of the probiotics tested. The starting
point is the claim relating to the organism’s strain stated on the
label of, and the quantity of micro-organisms contained in,
some products on the market in South Africa. 
1. The study was done independently by a team of
microbiologists at the University of Ghent in Belgium, using
internationally recognised methods and experienced in
analysing products of this nature. The results were reviewed
and written up by an independent medical microbiologist, Dr
Elliott, reviewed by two senior peers prior to submission, and
reviewed by the SAMJ peer review committee before
publication. 
2. All the samples were sent to Belgium under the same
consignment conditions (cold-chain conditions) under which
Pharmadynamics and Thebe Pharmaceuticals import their
products from Scandinavia. 
3. Denaturing gradient gel electrophoresis (DGGE) is not a
method used to quantify bacteria but, as clearly stated in the
article, a culture-independent technique of direct identification
of bacterial strains in probiotic products. DGGE is an
internationally recognised method, validated by Temmerman et
al.,5,6 of evaluating bacterial strains in a sample especially where
multiple bacteria exist. Bergey’s Manual provides renowned and
approved methods of phenotypic culture-dependent analysis.
In the chapter on lactobacilli, one example states that the
identification of Lactobacillus acidophilus cannot be based on
simple phenotypic tests, to reliably distinguish it from 
L. gasseri, L. crispatus and L. amylovorus.  DGGE offers a new
validated method of more accurate strain identification of
bacteria than the traditional culture-dependent methods.
Where a product contains heat-killed bacteria, the DGGE
method and probably also PFGE and RAPD are not reliable
owing to denatured DNA. Only one product in the study
contained a heat-killed lactobacillus. That was Lactéol Forte,
not claimed as a probiotic but included in the study because it
is has been promoted as a probiotic (personal communication
with pharmacists). 
4. Experience through preparing and testing many samples
from different dosage forms has allowed the Ghent
microbiologists to develop a standardised and validated
protocol that most consistently provides the highest bacterial
counts. Furthermore, where growth was low or zero, a further
sample was submitted to the same triplicate procedure
(internationally recognised) as well as broth culture to give the
bacteria the best chance (personal communication with Dr
Temmerman). This standardisation is also the reason why the
overall counts achieved in this analysis are lower than the
generally accepted counts for probiotic efficacy of between 107
and 1010 according to clinically proven doses of different
probiotic strains depending on their robustness and ability to
survive the human digestive tract. This standardisation further
meant that, for the purposes of interpretation of this study, the
cut-off count of 106  was used as a threshold value for
physiological probiotic effects and not higher as suggested in
the literature.7 Information on methodology was referenced in
the original article and exclusion of methodological detail from
the article does not detract from the conclusions.  Overall, we
maintain that the article is a fair and accurate interpretation of
the report received from the laboratory in Ghent, and therefore
of the quality of the probiotics randomly selected and analysed
at that point in time.
5. The Joint FAO/WHO working group guidelines for the
evaluation of probiotics in food advocate that the nomenclature
of the bacteria must conform to the current, scientifically
recognised names to prevent consumers and regulatory
agencies making assumptions about the identity of the real
bacterium being sold.8 While probiotic effects are strain-specific
and not species-specific, DGGE is capable of distinguishing
between Bifidobacterium longum and B. infantis. It is noted that
B. suis, B. infantis and B. longum are three different biovars and
should be unified as B. longum.9 Using the species names
infantis and longum interchangeably on labels creates
confusion which will probably be resolved when their
reclassification is published in the International Journal of
Systemic and Evolutionary Microbiology. 
6. The importance of strain identification is further
illustrated in a recent letter to pharmacists in South Africa
dated 20 February 2004 (J Smith, ‘Blatant misinformation on
probiotics’) which indicates that ‘they have proven that their
product yields millions of bacteria as claimed’. A second letter
to the pharmacists, dated 1 March 2004 (J Smith, ‘Levels of
viable cells per capsule’), reports counts of ‘viable cells’ in
various batches ranging from 30 to 150 million per capsule
with no identification.  The label claims that the product
contains ‘Lactic Acid Bacillus’ which could mean any one of
many lactobacilli or bifidobacteria. At present it is not known
what organism is in this product. If we don’t know what it is,
how do we know it’s safe?
7. Regular analysis of off-the-shelf probiotics is essential to
ensure and maintain quality, and as such the Complementary
Medicines Council of the Medicines Control Council is now
aware of the lack of regulation of this emerging market and has
established an investigation following a mandate issued by the
registrar of medicines.
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8. There are 55 probiotic products with registered NAPPI
codes available to pharmacies and health shops. Various
independent investigators, among whom is Dr Temmerman
from the University of Ghent, have analysed many different
probiotic products, of which the trade names are cited in the
references.5,10-12 In our opinion, using trade names is upfront,
honest, and enables clear communication with the health care
profession and the consumer needing to be educated to make a
decision about products that contain a number of difficult-to-
pronounce bacterial names (unlike products containing a
generic active like ‘paracetamol’). 
We contend that it is the manufacturer’s and distributor’s
minimum responsibility to ensure that their product complies
with its label claim, and that it is the right of the health care
worker as well as the consumer to know that the probiotic
product recommended or purchased contains what it claims to
contain. Accurate strain identification and viable count are
paramount. Proof of label claims would provide an appropriate
starting point for the industry to assist regulatory bodies in
drawing up guidelines for trustworthy probiotic products.
What needs to follow is a comparative review of the various
claimed health benefits and published literature of the different
probiotic strains.
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Probiotics — consensus of
analysis
To the Editor: I have some important issues to raise with
regard to the paper by Elliott and Teversham1 and the rebuttals
and opinions emanating from it.
While traditional starter cultures used in the dairy industry
are selected for their ability to rapidly produce desirable
organoleptic qualities of cultured dairy products, probiotic
bacteria are selected for the potential to provide specific health
or nutritional benefits following consumption. It must be
realised that such a selection addresses several criteria
including safety, technological and functional aspects.2 The
latter aspect has been extensively studied and reviewed, and
the editorial ‘Probiotics — how functional are they?’ by H J
Koornhof in the April SAMJ3 clearly demonstrates the
paramount fact about probiotics: their functionality in terms of
health benefits to man and animal. 
Two frequently overlooked and ignored aspects of safety and
technological difficulties remain. The safety of probiotic strains
is of major importance and guidelines for the safety assessment
have been addressed in several articles.4-6 The prerequisite of
microbiological safety is the identification of the strain. The
current state of evidence includes that probiotic effects are
strain-specific, meaning that correct identification of the strain
level is important to link a strain to a specific health effect as
well as to enable accurate surveillance and epidemiological
studies.7 Furthermore, the origin of the strain and its potential
GRAS (Generally Regarded as Safe) status,8 antibiotic resistance
profile and possible adverse side-effects are a few of the many
issues to be addressed in the process of pre-marketing a
probiotic.
To succeed in promoting the consumption of probiotic
products, the food industry has to meet the demands of the
consumer: in other words all probiotic foods should be safe,
functional and attractive to the senses. Before probiotic strains
can be delivered to consumers, they must first be capable of
being included into industrial fermentations. Next, they need
to survive and retain their functionality during storage as
frozen or freeze-dried cultures as well as in the commercial
food products to which they are added. Finally, the packaging
material and storage conditions are important factors
influencing the quality of the probiotic product during its shelf
life. In most cases, the probiotic properties are affected by the
way in which the strain or culture has been produced,9
meaning that each strain and its production process should be
characterised extensively in order to enable an effective
probiotic product to enter the consumer market. 
Regulatory and product labelling issues in the functional
foods area (probiotics are not considered separately in this
field) primarily involve two concerns: safety and assuring that
product labelling and promotion, while communicating the
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